@article{ACR4755,
author = {Nouf Alballa and Alanoud Alyousef and Albatool Alamari and Ahmed Abdullah Alhumidi and Mohammed Ayesh Zayed and Leena Zeitouni and Fahad Mohammed Alsaif},
title = {Hodgkin’s lymphoma in a patient on adalimumab treatment for psoriasis},
journal = {AME Case Reports},
volume = {2},
number = {0},
year = {2018},
keywords = {},
abstract = {Adalimumab is a human monoclonal antibody which targets tumor necrosis factor (TNF)-alpha. It is produced by recombinant DNA technology, using a mammalian cell expression system and is widely-known to treat a number of immune-mediated conditions, including psoriasis. There has been a growing concern regarding the possible association between TNF-alpha inhibitors and malignancy. In this case report, we describe the case of a 20-year-old woman, known to have been suffering from chronic plaque psoriasis for 12 years, and who developed Hodgkin’s lymphoma within five weeks of beginning adalimumab treatment.},
issn = {2523-1995}, url = {https://acr.amegroups.org/article/view/4755}
}